ABS, HHI and KSOE Collaborate on Green Hydrogen Production and Carbon Capture and Storage
4.11.2021 12:00:00 EET | Business Wire | Press release
At COP26, ABS, Hyundai Heavy Industries (HHI) and Korea Shipbuilding and Offshore Engineering (KSOE) have announced two landmark joint development projects (JDPs) to develop decarbonization technologies to support global sustainability ambitions.
The JDPs address green hydrogen production and offshore carbon capture and storage (CCS), two technologies which will be critical to achieving net zero.
ABS, HHI and KSOE will jointly develop technical guidance for green hydrogen production from offshore platforms as a key first step to the design and construction of a facility by 2025. The guidance will facilitate the development of production facilities providing a vital contribution in the growth of a global green hydrogen economy.
The project will utilize the electrolysis of seawater to generate green hydrogen. Later stages potentially include ABS Approval in Principle (AIP) and generic design approval, supporting engineering development right through to project construction.
A second offshore carbon capture JDP is focused on securing an AIP for HHI and KSOE’s design for a CO2 injection platform for offshore storage. The platform is designed to be able to store 400,000 tons of captured and liquefied CO2 every year from 2025.
The announcement is timed to coincide with the 2021 United Nations Climate Change Conference, COP26, in Glasgow, where the potential of green hydrogen to support global sustainability ambitions and the capture, utilization and sequestration of carbon will be central to the discussion. Green hydrogen is a fuel created using entirely renewable energy sources. Currently, only one percent of hydrogen fuel is produced this way.
“We are pleased to leverage our expertise in the green hydrogen and CCS platform pathway for decarbonization offshore. These projects are part of our continuous endeavors and commitment to a sustainable future that is aligned with HHI Group’s ESG vision, “Beyond Blue Forward to Green”. We also promise that HHI Group will encourage new value creation to lead the market, satisfying customers’ desire for the achievement of GHG zero emissions,” said Won Ho JOO, HHI Senior Executive Vice President and Chief Technical Officer.
“It is a quite meaningful technological milestone in obtaining the JDPs for these innovative green hydrogen and CCS platforms in offshore. KSOE believes our self-developed model will contribute to the global decarbonization effort. Also, we are preparing the development of the whole value chains of both CO2 and green hydrogen. In the near future, we will show the Perfect Net Zero technology,” said Sung Joon KIM, CTO of KSOE.
“Securing the required quantities of zero-carbon fuels to power our industry’s transition will require significant scaling up of the global renewable energy sources. Green hydrogen will certainly have a critical role to play but we are starting from a very low base and increasing production is an urgent global priority. Meanwhile, carbon capture is a potential game changer, and ABS is working to accelerate development of both the technology and the vessels required to make it viable,” said ABS Chairman, President and CEO, Christopher J. Wiernicki. “We are proud to be able to use our industry-leading offshore and sustainability expertise to support advances in these key areas of technology and the international decarbonization drive.”
▬▬
About ABS
ABS, a leading global provider of classification and technical advisory services to the marine and offshore industries, is committed to setting standards for safety and excellence in design and construction. Focused on safe and practical application of advanced technologies and digital solutions, ABS works with industry and clients to develop accurate and cost-effective compliance, optimized performance and operational efficiency for marine and offshore assets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005089/en/
Contact information
For more information, contact:
ABS Media Relations
glewis@eagle.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
